PureTech Health PLC

NASDAQ PRTC

Data sourced from

and

Download Data

PureTech Health PLC Return on Assets (ROA) 5 year CAGR for the year ending December 31, 2023: -0.85%

PureTech Health PLC Return on Assets (ROA) 5 year CAGR is -0.85% for the year ending December 31, 2023. Return on assets (ROA) measures the profitability of a company relative to its total assets. It is calculated by dividing the net income by the total assets. This ratio indicates how effectively a company utilizes its assets to generate profits. A higher ROA suggests a more efficient use of assets and indicates better profitability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

PureTech Health PLC Return on Assets (ROA) for the year ending December 31, 2022 was -5.27%, a 20.42% change year over year.
PureTech Health PLC Return on Assets (ROA) for the year ending December 31, 2021 was -6.63%, a -1,536.62% change year over year.
PureTech Health PLC Return on Assets (ROA) for the year ending December 31, 2020 was 0.46%, a -98.97% change year over year.
PureTech Health PLC Return on Assets (ROA) for the year ending December 31, 2019 was 44.75%, a 552.82% change year over year.

NASDAQ: PRTC

PureTech Health PLC

CEO	Ms. Daphne Zohar
IPO Date	Nov. 16, 2020
Location	United States
Headquarters	6 Tide Street, Boston, MA, United States, 02210
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends